Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Basic Research in Cardiology
Metadata
Title
A histamine H2 receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade
Publication date
01-11-2010
Published in
Basic Research in Cardiology / Issue 6/2010
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-010-0119-y

Other articles of this Issue 6/2010

Basic Research in Cardiology 6/2010 Go to the issue

Original Contribution

The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice

Contribution

TNFα protects cardiac mitochondria independently of its cell surface receptors

Original Contribution

BNP controls early load-dependent regulation of SERCA through calcineurin

Original Contribution

Long-term diabetes impairs repopulation of hematopoietic progenitor cells and dysregulates the cytokine expression in the bone marrow microenvironment in mice

Original Contribution

Ethanolamine is a novel STAT-3 dependent cardioprotective agent

Original Contribution

CCN1 promotes the differentiation of endothelial progenitor cells and reendothelialization in the early phase after vascular injury

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits